Palisade Bio Strengthens Board with Biotech Veterans Baltera and Zwick as PALI-2108 Advances Toward Phase 2 in IBD
核心洞察
Palisade Bio appointed Robert Baltera and Jordan Zwick to its Board of Directors, bringing decades of biopharma leadership, strategic transactions, and capital markets expertise.
The appointments come as the company's lead candidate PALI-2108, a once-daily oral PDE4 (搜索) inhibitor prodrug, advances toward Phase 2 development in ulcerative colitis (搜索) and Crohn's disease (搜索).
PALI-2108 has generated positive clinical data from a Phase 1a trial and two Phase 1b trials, including studies in ulcerative colitis (搜索) and fibrostenotic Crohn's disease (搜索).
Palisade Bio, Inc. (Nasdaq: PALI), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 (搜索) inhibitor prodrugs, announced on June 11, 2026 the appointment of Robert Baltera and Jordan Zwick to its Board of Directors. The board expansion comes as the company advances its lead program, PALI-2108, toward Phase 2 clinical development for inflammatory bowel disease (搜索) (IBD).
"We are pleased to welcome both Robert and Jordan to the Palisade Bio Board of Directors," said JD Finley, Chief Executive Officer of Palisade Bio. "Their combined expertise across biotechnology company building, strategic transactions, capital markets, operational execution and corporate governance will provide meaningful value as we continue advancing PALI-2108 through clinical development and execute on our long-term growth strategy."
Deep Industry Experience
Robert Baltera brings more than three decades of biopharmaceutical leadership to the board. He currently serves as a Senior Advisor at Frazier Life Sciences and sits on the Board of Directors of Inipharm. His track record includes serving as CEO of Amira Pharmaceuticals, which was sold to Bristol-Myers Squibb in 2011 for $475 million, and as Chairman of Mavupharma until its acquisition by AbbVie. He also served on the boards of Imago BioSciences, acquired by Merck, and Frazier Lifesciences Acquisition Corporation. Earlier in his career, Baltera spent 17 years at Amgen in various senior management positions.
"I am excited to join the Palisade Bio Board of Directors at such an important stage in the Company's development," said Baltera. "PALI-2108 has demonstrated a differentiated profile and the potential to address significant unmet needs in inflammatory bowel disease (搜索). With the program advancing toward Phase 2 development, I believe Palisade Bio is entering a critical period of growth and value creation."
Jordan Zwick, Co-Founder and Chief Business Officer of Mirador Therapeutics, brings extensive expertise in corporate strategy, business development, and capital markets. He served as a strategic advisor to Prometheus Biosciences prior to its acquisition by Merck in 2023 and to CrossBridge Bio through its acquisition by Eli Lilly in 2026. Zwick previously held leadership roles at Amarin Corporation, InflaRx N.V., Medtronic, Salix Pharmaceuticals, and Bausch Health.
"Palisade Bio represents a compelling opportunity at a pivotal stage in its evolution," said Zwick. "PALI-2108 has generated encouraging clinical data to date and is advancing toward several meaningful milestones. As the Company advances toward Phase 2 development, I believe it is well positioned to address a significant unmet medical need while creating meaningful value for shareholders."
PALI-2108: Targeted PDE4 (搜索) Inhibition for IBD
PALI-2108 is a once-daily oral PDE4 (搜索) inhibitor prodrug engineered for selective bioactivation in the ileum and colon. This design enables targeted PDE4 inhibition at sites of disease while allowing systemic distribution of the active drug. The candidate has generated positive clinical data from a Phase 1a trial and two Phase 1b clinical trials, including studies in ulcerative colitis (搜索) (UC) and fibrostenotic Crohn's disease (搜索) (FSCD).
Palisade Bio is now advancing PALI-2108 toward Phase 2 clinical studies in both UC and Crohn's disease (搜索). The company's differentiated prodrug platform and precision pharmacology strategy aim to transform proven PDE4 (搜索) biology into differentiated oral therapies for patients with chronic inflammatory and fibrotic diseases.